BACKGROUND: Facial emotion recognition deficits [FERD] have been consistently demonstrated in treated schizophrenia patients. FERD in treatment-naïve patients and the effect of antipsychotics are yet to be explored. AIMS: To examine for FERD in antipsychotic-naïve schizophrenia patients and the effect of short-term atypical antipsychotic treatment on FERD. METHODS: Twenty-five antipsychotic-naïve schizophrenia [DSM-IV] patients and 30 age-, sex-, and education-matched healthy control subjects were assessed for FERD using the Tool for Recognition of Emotions in Neuropsychiatric DisorderS [TRENDS] - a culturally sensitive and valid tool. Psychopathology was assessed using SAPS and SANS. Performance of patients on TRENDS and psychopathology was re-assessed after short-term exposure to risperidone. RESULTS: At baseline, the patients made significantly greater errors in recognition of negative emotions of fear and disgust which improved on follow-up. This improvement was influenced by severity of baseline negative symptoms. CONCLUSION: Risperidone treatment can improve disgust recognition deficits in patients with schizophrenia.
BACKGROUND:Facial emotion recognition deficits [FERD] have been consistently demonstrated in treated schizophreniapatients. FERD in treatment-naïve patients and the effect of antipsychotics are yet to be explored. AIMS: To examine for FERD in antipsychotic-naïve schizophreniapatients and the effect of short-term atypical antipsychotic treatment on FERD. METHODS: Twenty-five antipsychotic-naïve schizophrenia [DSM-IV] patients and 30 age-, sex-, and education-matched healthy control subjects were assessed for FERD using the Tool for Recognition of Emotions in Neuropsychiatric DisorderS [TRENDS] - a culturally sensitive and valid tool. Psychopathology was assessed using SAPS and SANS. Performance of patients on TRENDS and psychopathology was re-assessed after short-term exposure to risperidone. RESULTS: At baseline, the patients made significantly greater errors in recognition of negative emotions of fear and disgust which improved on follow-up. This improvement was influenced by severity of baseline negative symptoms. CONCLUSION:Risperidone treatment can improve disgust recognition deficits in patients with schizophrenia.
Authors: Michael F Green; Carrie E Bearden; Tyrone D Cannon; Alan P Fiske; Gerhard S Hellemann; William P Horan; Kimmy Kee; Robert S Kern; Junghee Lee; Mark J Sergi; Kenneth L Subotnik; Catherine A Sugar; Joseph Ventura; Cindy M Yee; Keith H Nuechterlein Journal: Schizophr Bull Date: 2011-02-23 Impact factor: 9.306
Authors: William P Horan; Michael F Green; Michael DeGroot; Alan Fiske; Gerhard Hellemann; Kimmy Kee; Robert S Kern; Junghee Lee; Mark J Sergi; Kenneth L Subotnik; Catherine A Sugar; Joseph Ventura; Keith H Nuechterlein Journal: Schizophr Bull Date: 2011-03-07 Impact factor: 9.306
Authors: Nora I Muros; Arturo S García; Cristina Forner; Pablo López-Arcas; Guillermo Lahera; Roberto Rodriguez-Jimenez; Karen N Nieto; José Miguel Latorre; Antonio Fernández-Caballero; Patricia Fernández-Sotos Journal: J Clin Med Date: 2021-04-28 Impact factor: 4.241
Authors: Wilhelmina A M Vingerhoets; Oswald J N Bloemen; Geor Bakker; Therese A M J van Amelsvoort Journal: Front Psychiatry Date: 2013-12-04 Impact factor: 4.157